Longboard Pharmaceuticals... (LBPH)
NASDAQ: LBPH
· Real-Time Price · USD
59.98
null (null%)
At close: Nov 29, 2024, 7:00 PM
Longboard Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 8K | 8K | 8K | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 4K | 5K | 5K | 5K | 5K | 5K | 5K | 5K | 5K | 4K | 2K | 1K | n/a | n/a | n/a |
Gross Profit | 4K | 3K | 3K | 3K | -5K | -5K | -5K | -5K | -5K | -4K | -2K | -1K | n/a | n/a | n/a |
Operating Income | -87.45M | -72.91M | -62.91M | -56.76M | -52.91M | -51.22M | -47.14M | -44.8M | -41.87M | -36.34M | -31.76M | -27.84M | -29.15M | -25.35M | -19.93M |
Interest Income | 11.26M | 8.27M | 5.02M | 2.4M | 2.23M | 1.85M | 1.32M | 837K | 470K | 206K | 92K | 64K | 40K | 17K | 4K |
Pretax Income | -76.34M | -64.74M | -57.95M | -54.42M | -50.73M | -49.4M | -45.8M | -43.95M | -41.37M | -36.12M | -31.7M | -27.8M | -29.13M | -25.34M | -19.93M |
Net Income | -76.34M | -64.74M | -57.95M | -53.92M | -49.85M | -48.22M | -44.63M | -43.27M | -41.09M | -36.12M | -31.7M | -27.8M | -29.13M | -25.34M | -19.93M |
Selling & General & Admin | 20.19M | 16.61M | 14.51M | 13.01M | 12.17M | 11.55M | 11.09M | 10.16M | 10.05M | 9.83M | 9.26M | 8.06M | 13.58M | 12.26M | 10.96M |
Research & Development | 67.26M | 56.3M | 48.39M | 43.75M | 40.75M | 39.66M | 36.05M | 34.64M | 31.81M | 26.5M | 22.5M | 19.77M | 15.58M | 13.09M | 8.97M |
Other Expenses | -83K | -97K | -67K | -68K | -50K | -35K | 15K | 16K | 22K | 8K | -31K | -22K | -19K | -6K | n/a |
Operating Expenses | 87.45M | 72.91M | 62.91M | 56.76M | 52.91M | 51.22M | 47.14M | 44.8M | 41.87M | 36.34M | 31.76M | 27.84M | 29.15M | 25.35M | 19.93M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | -1K | -1K | -1K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 87.45M | 72.91M | 62.91M | 56.76M | 52.91M | 51.22M | 47.14M | 44.8M | 41.87M | 36.34M | 31.76M | 27.84M | 29.15M | 25.35M | 19.93M |
Income Tax Expense | -44.28K | -45.28K | -43.28K | -507K | -889K | -1.18M | -1.18M | -702K | -345K | -57K | -57K | -25K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 38.96M | 38.88M | 35.32M | 23.92M | 23.49M | 22.97M | 20.41M | 17.21M | 17.17M | 17.13M | 17.09M | 17.03M | 16.87M | 16.83M | 16.87M |
Shares Outstanding (Diluted) | 38.96M | 38.88M | 35.32M | 23.92M | 23.49M | 22.97M | 20.41M | 17.21M | 17.17M | 17.13M | 17.09M | 17.03M | 16.87M | 16.83M | 16.87M |
EPS (Basic) | -2.24 | -2.16 | -2.25 | -2.37 | -2.38 | -2.49 | -2.51 | -2.53 | -2.41 | -2.13 | -1.87 | -1.65 | -1.73 | -1.5 | -1.18 |
EPS (Diluted) | -2.24 | -2.16 | -2.25 | -2.37 | -2.38 | -2.49 | -2.51 | -2.53 | -2.41 | -2.13 | -1.87 | -1.65 | -1.73 | -1.5 | -1.18 |
EBITDA | -87.44M | -72.9M | -62.9M | -56.75M | -52.91M | -51.21M | -47.13M | -44.79M | -41.86M | -36.33M | -31.75M | -27.84M | -29.15M | -22.8M | -17.38M |
EBIT | -87.45M | -72.91M | -62.91M | -56.76M | -52.91M | -51.22M | -47.14M | -44.8M | -41.87M | -36.34M | -31.76M | -27.84M | -29.15M | -25.35M | -19.93M |
Depreciation & Amortization | 5K | 5K | 5K | 5K | 5K | 5K | 5K | 5K | 5K | 6.36M | 13.34M | 19.05M | 21.75M | 17.95M | 12.53M |